Availability of Data and Material
None
References
Simon A, Asli B, Braun-Falco M, De Koning H, Fermand J-P, Grattan C, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68(5):562–8.
de Koning HD. Schnitzler’s syndrome: lessons from 281 cases. Clin Transl Allergy. 2014;4:41.
Jani P, Vissing MB, Ahmed S, Sluzevich JC, Aulakh S, Alegria V, et al. Ibrutinib for the management of Schnitzler syndrome: a novel therapy for a rare condition. J Oncol Pract. 2018;14(6):387–8.
Pathak S, Rowczenio DM, Owen RG, Doody GM, Newton DJ, Taylor C, et al. Exploratory study of MYD88 L265P, rare NLRP3 variants, and clonal hematopoiesis prevalence in patients with Schnitzler syndrome. Arthritis Rheumatol. 2019;71(12):2121–5.
Liu X, Pichulik T, Wolz O-O, Dang T-M, Stutz A, Dillen C, et al. Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. J Allergy Clin Immunol. 2017;140(4):1054–1067.e10.
Acknowledgements
Authors acknowledge Dr. Tomowiak Cecile for the advices and help.
Author information
Authors and Affiliations
Contributions
FC and SC wrote the manuscript. FC, SC, CL, RS, and SVD bring biological and clinical data, generated results, and corrected the final manuscript.
Corresponding author
Ethics declarations
Ethics Approval
Not relevant.
Consent to Participate
Not relevant.
Consent for Publication
Not relevant.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Claves, F., Siest, R., Lefebvre, C. et al. Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma. J Clin Immunol 41, 1380–1383 (2021). https://doi.org/10.1007/s10875-021-01038-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-021-01038-y